Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone

What Was Tested

This clinical trial, phase ii paper looks at Cosyntropin in the context of acne.

This report provides details of patients who developed laboratory signs of hypothalamic-pituitary-adrenal (HPA) axis suppression without clinical signs of adrenal suppression during the clascoterone development program.

Who Took Part

By PubMed's age tags, the people studied were children, teenagers, young adults and adults, both men and women.

Two open-label, multicenter, Phase 2 trials evaluated HPA axis suppression in patients with moderate-to-severe acne vulgaris.

Study 1 (NCT01831960) enrolled cohorts of adults =>18 years of age and adolescents =>12 to <18 years of age.

How the Study Was Run

The design is described as open-label and multicenter.

Nothing was hidden in this open-label Cosyntropin study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

The timeline in the abstract includes 14 days.

Study 2 (NCT02720627) enrolled adolescents 9 to <12 years of age.

Patients applied clascoterone twice daily at maximum-exposure dosages for 14 days.

Adrenal suppression was evaluated via cosyntropin stimulation test (CST) at baseline and day 14.

Patients with an abnormal CST result (serum cortisol level =<18 µg/dL) had a follow-up CST approximately 4 weeks later.

Other safety assessments included adverse events (AEs), physical examination/vital signs, and electrocardiography.

What Was Measured

PubMed files the paper under topics including Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Acne Vulgaris, Hydrocortisone, Cortodoxone, Administration, Cutaneous and Skin Cream.

What This Means in Plain Language

The paper is an open-label and multicenter study of Cosyntropin in people with acne over 14 days.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Journal of drugs in dermatology : JDD), a journal based in United States.

More context: the Cosyntropin compound page, Acne research.